Articles Related to T1
Genetic Relatedness and Characterization of O25b-B2-ST131, in Stool Isolates of Extended-Spectrum Cephalosporin-Resistant Escherichia Coli Strains in Healthy Children under 10 Years of Age
Background and Purpose: Escherichia coli (E. coli) is one of the multidrug-resistant pathogens, producing extendedspectrum beta-lactamase enzymes. Molecular typing of this pathogen can be useful for determining the source of dissemination and transfer of resistance and virulence genes of these isolates. Considering the significance of infection in children, in this study, we examined the stool flora of children (<10 years) to show the characteristics and clonal relationship of the isolates.
Global Correction of T10 Non-uniformity in mMR Breast Coil with Multiple Tube Phantom-based Technique and its Validation in Breast MRI: a Feasibility Study
Non-uniform native T1 (T10) distribution influences reliable measurement of Ktrans: a pharmacokinetic parameter (Ktrans) that quantitatively measures neovascularization of the tumor tissue that has been used for the classification of malignant breast lesions and to monitor therapy response.
Carotid Body Tumor - Case Report and Review of the Literature
The paraganglioma of the carotid sinus is a relatively rare tumor, which represents the majority of paraganglioma of the head and neck (60-70%).
Characterization of Screen-Printed Nickel Oxide Electrodes for p-type Dye-Sensitized Solar Cells
Mesoporous NiO films obtained via screen-printing deposition of a newly formulated paste containing preformed NiO-nanospheres have been employed as nanostructured photocathodes of p-type dye-sensitized solar cells (p-DSCs).
Phase II Trial of Lower Dose Bevacizumab and Irinotecan in Relapsed High Grade Gliomas
Relapsed high-grade gliomas (HGG) respond poorly to known chemotherapeutic agents with a median survival of 3 to 6 months. Several phase II trials of Bevacizumab for salvage therapy, reported excellent response rates. The optimal dose of Bevacizumab in GBM has not been defined to date. We performed a prospective phase II trial of bevacizumab using 5 mg/kg every 2 weeks.
